University of Colorado Cancer Center Member Urges Nuanced Approach in Myeloma Drug Decision

Christopher Lieu, MD, Associate Director of Clinical Research at CU Cancer Center, highlighted concerns about overtreatment and infection risk as the FDA panel weighed early use of daratumumab. Despite voting in favor, he stressed the urgent need for predictive tools to better identify patients who truly benefit.